CONMED (NYSE:CNMD) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
CONMED (NYSE:CNMD) had its price target raised by analysts at Wells Fargo & Company from $41.00 to $42.00. They now have an "equal weight" rating on the stock.
CONMED (NYSE:CNMD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Conmed Corp (CNMD) Q4 2025 Earnings Call Highlights: Strong Orthopedic Sales Drive Growth ... [Yahoo! Finance]
CONMED Q4 Earnings Call Highlights [Yahoo! Finance]